2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private PlacementPsyched Wellness Commences Pre-Clinical Trials of Amanita MuscariaHavn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an

Technical420 Site Search

Returned 121 result(s).

Pure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction Platform

Last month, we published an article that highlighted Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) as an attractive play on the cannabis and psychedelic extract market. Our thesis is based off the strength of the management team, the structure of the business, and the potential catalysts for…

Psyched Wellness’ Mycological Research Continues To Take Serious Strides Forward

In late December, Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) reported to have started to research the impact that muscimol has on a variety of ailments and we are impressed with how the story has advanced since then. Less than two weeks after Psyched announced that it started…

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a…

Pure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction Platform

In December, we highlighted Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) after it was granted a Standard Processing License by Health Canada in late September. The plant-based extraction company is levered to the cannabis and the psychedelic extract market and we consider it to be a differentiated story with…

MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce the closing of a non-brokered private placement offering by the Company (the "Offering) of an aggregate of 8,000,000 common shares (the "Common Shares") at a price of CDN$0.30 per Common Share for…

CYBIN Provides Update on Patent Filings & Development of Therapeutics Program

Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to provide an update on its on its eight patent filings, which cover the Company’s novel therapeutics, delivery mechanisms and treatment regiments. Cybin’s updated corporate presentation will be available at www.cybin.com. The Company is…

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp., developers of a vertically integrated functional mushroom brand focused…

Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing

Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds…

3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical Trials

Although 2020 was a banner year for the psychedelic therapy market, we expect 2021 to be an even better year for the sector as leading biotech firms are set to report Phase 3 Food and Drug Administration (FDA) clinical trial data. We have seen the psychedelic sector evolve over the…

Psyched Wellness Has Commenced Research on Muscimol for Various Ailments

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (formerly Duncan Park Holdings Corporation) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has commenced research on Muscimol for various ailments, with a focus…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link